Francisco M. Marty,Per Ljungman,Roy F. Chemaly,Johan Maertens,Sanjeet Dadwal,Rafael F. Duarte,Shariq Haider,Andrew J. Ullmann,Yuta Katayama,Janice Brown,Kathleen M. Mullane,Michael Boeckh,Emily A. Blumberg,Anne Bergeron,David R. Snydman,Yoshinobu Kanda,Mark J. DiNubile,Valerie Teal,Hong Wan,Yoshihiko Murata,Nicholas A. Kartsonis,Randi Y. Leavitt,Cyrus Badshah
Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV–terminase complex.